Llovet JM, Castet F, Heikenwalder M, Maini MK, Mazzaferro V, Pinato DJ, et al. Immunotherapies for hepatocellular carcinoma. Nat Rev Clin Oncol. 2022;19(3):151–72.

Article  CAS  PubMed  Google Scholar 

He P, Wan H, Wan J, Jiang H, Yang Y, Xie K, et al. Systemic therapies in hepatocellular carcinoma: existing and emerging biomarkers for treatment response. Front Oncol. 2022;12:1015527.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shahini E, Pasculli G, Solimando AG, Tiribelli C, Cozzolongo R, Giannelli G. Updating the clinical application of blood biomarkers and their algorithms in the diagnosis and surveillance of hepatocellular carcinoma: a critical review. Int J Mol Sci. 2023;24(5):4286.

Article  CAS  PubMed  PubMed Central  Google Scholar 

El Jabbour T, Lagana SM, Lee H. Update on hepatocellular carcinoma: pathologists’ review. World J Gastroenterol. 2019;25(14):1653–65.

Article  PubMed  PubMed Central  Google Scholar 

De Stefano F, Chacon E, Turcios L, Marti F, Gedaly R. Novel biomarkers in hepatocellular carcinoma. Dig Liver Dis. 2018;50(11):1115–23.

Article  PubMed  Google Scholar 

Damaskos C, Garmpis N, Dimitroulis D, Garmpi A, Psilopatis I, Sarantis P, et al. Targeted therapies for hepatocellular carcinoma treatment: a new era ahead-a systematic review. Int J Mol Sci. 2022;23(22):14117.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Llovet JM, Montal R, Sia D, Finn RS. Molecular therapies and precision medicine for hepatocellular carcinoma. Nat Rev Clin Oncol. 2018;15(10):599–616.

Article  PubMed  Google Scholar 

Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7(1):6.

Article  PubMed  Google Scholar 

Mighell TL, Evans-Dutson S, O’Roak BJ. A saturation mutagenesis approach to understanding PTEN lipid phosphatase activity and genotype-phenotype relationships. Am J Hum Genet. 2018;102(5):943–55.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Luongo F, Colonna F, Calapa F, Vitale S, Fiori ME, De Maria R. PTEN tumor-suppressor: the dam of stemness in cancer. Cancers (Basel). 2019;11(8):1076.

Article  CAS  PubMed  Google Scholar 

Harima Y, Sawada S, Nagata K, Sougawa M, Ostapenko V, Ohnishi T. Mutation of the PTEN gene in advanced cervical cancer correlated with tumor progression and poor outcome after radiotherapy. Int J Oncol. 2001;18(3):493–7.

CAS  PubMed  Google Scholar 

Zhang L, Liu C, Zhang B, Zheng J, Singh P, Bshara W, et al. PTEN loss expands the histopathological diversity and lineage plasticity of lung cancers initiated by Rb1/Trp53 deletion. J Thorac Oncol. 2022;18(3):324–38.

Article  PubMed  Google Scholar 

Shearn CT, Petersen DR. Understanding the tumor suppressor PTEN in chronic alcoholism and hepatocellular carcinoma. Adv Exp Med Biol. 2015;815:173–84.

Article  CAS  PubMed  Google Scholar 

Khalid A, Hussain T, Manzoor S, Saalim M, Khaliq S. PTEN: a potential prognostic marker in virus-induced hepatocellular carcinoma. Tumour Biol. 2017;39(6):1010428317705754.

Article  PubMed  Google Scholar 

Hill R, Wu H. PTEN, stem cells, and cancer stem cells. J Biol Chem. 2009;284(18):11755–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Malta TM, Sokolov A, Gentles AJ, Burzykowski T, Poisson L, Weinstein JN, et al. Machine learning identifies stemness features associated with oncogenic dedifferentiation. Cell. 2018;173(2):338-354.e15.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yoshihara K, Shahmoradgoli M, Martinez E, Vegesna R, Kim H, Torres-Garcia W, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013;4:2612.

Article  PubMed  Google Scholar 

Charoentong P, Finotello F, Angelova M, Mayer C, Efremova M, Rieder D, et al. Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade. Cell Rep. 2017;18(1):248–62.

Article  CAS  PubMed  Google Scholar 

Bagaev A, Kotlov N, Nomie K, Svekolkin V, Gafurov A, Isaeva O, et al. Conserved pan-cancer microenvironment subtypes predict response to immunotherapy. Cancer Cell. 2021;39(6):845-865.e7.

Article  CAS  PubMed  Google Scholar 

Sanchez-Vega F, Mina M, Armenia J, Chatila WK, Luna A, La KC, et al. Oncogenic signaling pathways in the cancer genome atlas. Cell. 2018;173(2):321-337.e10.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mariathasan S, Turley SJ, Nickles D, Castiglioni A, Yuen K, Wang Y, et al. TGFbeta attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018;554(7693):544–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hugo W, Zaretsky JM, Sun L, Song C, Moreno BH, Hu-Lieskovan S, et al. Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell. 2016;165(1):35–44.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jiang P, Gu S, Pan D, Fu J, Sahu A, Hu X, et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med. 2018;24(10):1550–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yin Y, Shen WH. PTEN: a new guardian of the genome. Oncogene. 2008;27(41):5443–53.

Article  CAS  PubMed  Google Scholar 

Alvarez-Garcia V, Tawil Y, Wise HM, Leslie NR. Mechanisms of PTEN loss in cancer: it’s all about diversity. Semin Cancer Biol. 2019;59:66–79.

Article  CAS  PubMed  Google Scholar 

Vinciguerra M, Foti M. PTEN at the crossroad of metabolic diseases and cancer in the liver. Ann Hepatol. 2008;7(3):192–9.

Article  CAS  PubMed  Google Scholar 

Vidotto T, Melo CM, Castelli E, Koti M, Dos Reis RB, Squire JA. Emerging role of PTEN loss in evasion of the immune response to tumours. Br J Cancer. 2020;122(12):1732–43.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Horie Y, Suzuki A, Kataoka E, Sasaki T, Hamada K, Sasaki J, et al. Hepatocyte-specific PTEN deficiency results in steatohepatitis and hepatocellular carcinomas. J Clin Invest. 2004;113(12):1774–83.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kato T, Yamada T, Nakamura H, Igarashi A, Anders RA, Sesaki H, et al. The loss of nuclear PTEN increases tumorigenesis in a preclinical mouse model for hepatocellular carcinoma. iScience. 2020;23(10): 101548.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Salmena L, Carracedo A, Pandolfi PP. Tenets of PTEN tumor suppression. Cell. 2008;133(3):403–14.

Article  CAS  PubMed  Google Scholar 

Brandmaier A, Hou SQ, Shen WH. Cell cycle control by PTEN. J Mol Biol. 2017;429(15):2265–77.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Aquila S, Santoro M, Caputo A, Panno ML, Pezzi V, De Amicis F. The tumor suppressor PTEN as molecular switch node regulating cell metabolism and autophagy: implications in immune system and tumor microenvironment. Cells. 2020;9(7):1725.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhou J, Li X. Association of PTEN expression with liver function and inflammatory changes in patients with liver cancer after chemotherapy. Oncol Lett. 2018;16(5):6633–7.

CAS  PubMed  PubMed Central  Google Scholar 

Peng W, Chen JQ, Liu C, Malu S, Creasy C, Tetzlaff MT, et al. Loss of PTEN promotes resistance to T cell-mediated immunotherapy. Cancer Discov. 2016;6(2):202–16.

Article  CAS  PubMed  Google Scholar 

Qi S, Li B, Yang T, Liu Y, Cao S, He X, et al. Validation of Bmi1 as a therapeutic target of hepatocellular carcinoma in mice. Int J Mol Sci. 2014;15(11):20004–21.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Benjamin DI, Cozzo A, Ji X, Roberts LS, Louie SM, Mulvihill MM, et al. Ether lipid generating enzyme AGPS alt